← All trials
NCT06438471
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2024
- Primary completion
- Nov 30, 2025
- Completion date
- Dec 31, 2025
- First posted
- Jun 3, 2024
- Last posted
- Oct 24, 2024
- Enrollment
- 36
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- EicOsis Human Health Inc.Lead sponsor
- EicOsis Human Health Inc.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.